ESC 2019 | CONDI-2ERIC-PPCI: Final Blow Against Ischemic Pre-Conditioning in Primary Angioplasty

Remote ischemic conditioning does not offer any clinical benefit to patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty, according to this study presented on Sunday at the European Society of Cardiology Congress 2019.

Prior studies were limited and small, but this analysis seems to provide definitive evidence with regard to ischemic pre-conditioning. The way to improve must be found somewhere else.

The study randomized 5401 patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty to remote ischemic pre-conditioning (either in the ambulance or on hospital admission) or not. The pre-conditioning procedure was performed intermittently through four cycles of 5-minute inflation of a blood-pressure cuff.


Read also: ESC 2019 | THEMIS-PCI: Unlike in the Main Study, Here Ticagrelor Is Indeed Effective.


After 1 year of follow-up, there were no differences between the control and active groups regarding the primary endpoint of cardiac death or heart failure readmission. There were also no differences in the secondary endpoints (a composite of cardiac death and heart failure readmission at 30 days, and major adverse cardiac or cerebrovascular events [MACCE] at 30 days and 1 year).

Results were consistent across subgroups (by age, diabetes status, infarct location, final TIMI flow, and time elapsed from first medical contact to balloon inflation).

Other forms of ischemic pre-conditioning, such as pharmacologic compounds (exenatide and cyclosporin) or mechanical postconditioning and balloon reinflation in the coronary artery, have also failed.

Original Title: Effect of remote ischaemic conditioning on clinical outcomes in patients with STEMI undergoing primary PCI: the CONDI-2/ERIC-PPCI trial.

Reference: Botker HE. Presentado el 1 de septiembre en el ESC 2019. Paris, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...